Trial Profile
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Postural orthostatic tachycardia syndrome
- Focus Registrational; Therapeutic Use
- 23 Feb 2021 Primary endpoint (Change in Heart Rate) has been met, according to Results published in the Journal of the American College of Cardiology.
- 23 Feb 2021 Results published in the Journal of the American College of Cardiology.
- 15 Feb 2021 Results presented in the University of California, San Diego Media Release.